Follow-up-study of COPD Patients and Healthy Controls for Evaluation of Predictive Non-coding RNA Biomarkers
NCT ID: NCT02522026
Last Updated: 2025-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
116 participants
OBSERVATIONAL
2015-08-31
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Second Follow-up Study of COPD Patients and Healthy Controls for Evaluation of Predictive Non-coding RNA Biomarkers
NCT04895124
European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00722267
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
NCT00292552
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
NCT01780298
A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment
NCT00772733
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunteers
No interventions assigned to this group
Healthy smokers
No interventions assigned to this group
COPD GOLD1
No interventions assigned to this group
COPD GOLD2
No interventions assigned to this group
COPD GOLD3/4
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able and willing to give written informed consent
* Not pregnant, as confirmed by pregnancy test
Exclusion Criteria
* Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study or impact on subject safety
* Has experienced a significant upper or lower respiratory tract infection incl. moderate or severe exacerbation (requiring oral corticosteroid, antibiotics or hospitalisation) within the last 4 weeks. All courses of oral corticosteroids and antibiotics must be completed at least 4 weeks before study start
* Clinically significant pathological findings in safety laboratory tests having an impact on study participation.
* Actual drug or alcohol abuse.
* Suspected inability to understand and follow protocol requirements, instructions, study-related restrictions, and to understand nature, scope, and possible consequences of the study.
* Being a vulnerable subject (dependent, in detention, or without mental capacity)
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fraunhofer-Institute of Toxicology and Experimental Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Jens Hohlfeld, MD
Division Director Airway Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens M Hohlfeld, Prof
Role: PRINCIPAL_INVESTIGATOR
Fraunhofer Institute for Toxicology and Experimental Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fraunhofer-Institute for Toxicology and Experimental Medicine
Hanover, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-01 RIBO II
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.